CTOs on the Move


 
Color`s mission is to help people lead the healthiest lives that science and medicine can offer. We launched in April 2015 with a simple, affordable genetic test to help people understand their risk for hereditary cancer. In 2017, we added coverage for hereditary heart conditions.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.color.com
  • 831 Mitten Rd
    Burlingame, CA USA 94010
  • Phone: N/A

Executives

Name Title Contact Details
Coe Salzgeber
Senior Director, Data & Infrastructure Profile
Lisa Hall
Chief Information Security Officer Profile

Funding

Color raised $75M on 01/14/2020
Color raised $167M on 01/04/2021
Color raised $100M on 11/09/2021

Similar Companies

Kowa Research Institute

Kowa Research Institute is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Polarity TE

PolarityTE, is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients` own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient`s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine.

Shasqi

Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery.

ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eidos Therapeutics

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.